Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26052308 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Shoichi Kimura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Liver Neoplasms, Hepatocyte Growth Factor, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture and Japan Society for Promotion of Science, Japan, Grant-in-Aid for Scientific Research, Ministry of Education, Science, Sports and Culture and Japan Society for Promotion of Science, Japan.
Abstract (Originalsprache)
The liver is the most lethal metastatic site in castration-resistant prostate cancer (CRPC). Overexpression of MET protein has been reported in CRPC, and MET is an important driver gene in androgen-independent CRPC cells. Mouse CRPC cell line CRTC2 was established by subcutaneous injection of hormone-sensitive PC cells (TRAMP-C2) in castrated nude mice. CRCT2/luc2 cells were injected into the spleen of castrated nude mice, and liver metastasis was confirmed at 2 weeks post-injection. We administered MET inhibitor (MET-I) and HGF activator inhibitor (HGFA-I) to this liver metastasis model and assessed the therapeutic effect. After intrasplenic injection, CRTC2 showed a higher incidence of liver metastasis whereas no metastasis was observed in TRAMP-C2. Microarray analysis revealed increased expression of HGF, MET, and HPN, HGFAC (encoding HGF activating proteases) in liver metastasis. Proliferation of CRCT2 was significantly inhibited by co-administration of MET-I and HGFA-I by in vitro analysis with HGF-enriched condition. In an analysis of the mouse model, the combination-therapy group showed the strongest reduction for liver metastasis. Immunohistochemical staining also revealed the strongest decrease in phosphorylation of MET in the combination-therapy group. Co-culture with HGF-expressed mouse fibroblasts showed attenuation of the inhibitory effect of MET-I; however, additional HGFA-I overcame the resistance. We established an androgen-independent CRPC cell line, CRTC2, and liver metastasis model in mice. Significant effect was confirmed by combined treatment of MET-I and HGFA-I by in vitro and in vivo analysis. The results suggested the importance of combined treatment with both MET- and HGF-targeting agents in the treatment of HGF-enriched conditions including liver metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
- Institute for Tenure Track Promotion, University of Miyazaki, Miyazaki 889-1692, Japan.
- Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan.
- Section of Oncopathology and Morphological Pathology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
- Organization for Promotion of Research and Industry Academic Regional Collaboration, University of Miyazaki, Miyazaki 889-1692, Japan.
ORCID-Profile: Shoichi Kimura, Satoshi Iwano, Makiko Kawaguchi, Tsuyoshi Fukushima, Hiroaki Kataoka
Förderung
- Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture and Japan Society for Promotion of Science, Japan
- Grant-in-Aid for Scientific Research
- Ministry of Education, Science, Sports and Culture and Japan Society for Promotion of Science, Japan
Zitieren
APA
Kimura, S., Iwano, S., Akioka, T., Kuchimaru, T., Kawaguchi, M., Fukushima, T., Sato, Y., Kataoka, H., Kamoto, T., Mukai, S., & Sawada, A. (2025). Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052308
Vancouver
Kimura S, Iwano S, Akioka T, Kuchimaru T, Kawaguchi M, Fukushima T, et al. Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052308
BibTeX
@article{Kimura2025,
author = {Kimura, Shoichi and Iwano, Satoshi and Akioka, Takahiro and Kuchimaru, Takahiro and Kawaguchi, Makiko and Fukushima, Tsuyoshi and Sato, Yuichiro and Kataoka, Hiroaki and Kamoto, Toshiyuki and Mukai, Shoichiro and Sawada, Atsuro},
title = {Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26052308}
}
EUVIMED